// App-Quantinova.ai

3276 : Evaluation of the Bcl-2 inhibitor ABT-199 in xenograft models of acute lymphoblastic leukemia by the pediatric preclinical testing program

Researchers

Presenter

  • Santi Suryani

Principal Investigators

  • Kathryn Evans

  • Jennifer Richmond

  • Alissa Robbins

  • Lauryn Bracken

  • Raushan Kurmasheva

  • Peter J. Houghton

  • Malcolm A. Smith

  • Richard B. Lock

Medical Centers

  • Centre for childhood cancer, Nationwide Childrens Hospital, Columbus, OH

  • Leukaemia Biology, Childrens Cancer Institute, Sydney, NSW, Australia

  • Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD

Locations

  • United States

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Chronic Lymphocytic Leukemia

  • Thrombocytopenia

  • T-cell acute lymphoblastic leukemia

  • Solid malignancies

Biomarkers

  • Myeloid Cell Leukemia 1

  • B-cell lymphoma 2

Drug/Treatment

  • Navitoclax

  • Venetoclax

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved